Paul A. Ainsworth, director in the firm’s Litigation Group, is quoted in the "Government" section of Bloomberg BNA’s article, “Hospira Can't Get Helsinn Aloxi Suit Dismissed.”
In the article, Mr. Ainsworth discusses the notable decision made by the U.S. District Court for the District of New Jersey in Helsinn Healthcare S.A. v. Hospira, Inc., in which the Court decided not to dismiss Helsinn Healthcare’s patent infringement complaint against Hospira.
“The New Jersey court's decision in Helsinn v. Hospira is predictably in line with the Federal Circuit's latest ruling in Acorda,” said Mr. Ainsworth. The result in the case is not surprising because the Federal Circuit's analysis relied on facts that are typical to most, if not all, ANDA filers, he continued.
Click the link below to see the full article on pages 8-9 (506-507 in Bloomberg BNA).
[Reproduced with permission from Pharmaceutical Law & Industry Report, 14 PLIR 506 (Apr. 8, 2016). Copyright 2016 by The Bureau of National Affairs, Inc. (800-372-1033) <http://www.bna.com>]